CA3040014C - Formulation pharmaceutique - Google Patents

Formulation pharmaceutique

Info

Publication number
CA3040014C
CA3040014C CA3040014A CA3040014A CA3040014C CA 3040014 C CA3040014 C CA 3040014C CA 3040014 A CA3040014 A CA 3040014A CA 3040014 A CA3040014 A CA 3040014A CA 3040014 C CA3040014 C CA 3040014C
Authority
CA
Canada
Prior art keywords
film
weight
alginate
sumatriptan
monovalent cation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3040014A
Other languages
English (en)
Other versions
CA3040014A1 (fr
Inventor
Scott Boyer
Fredrik Hubinette
Leif Ingemarsson
Susan Suchdev
Original Assignee
Klaria Pharma Holding AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding AB filed Critical Klaria Pharma Holding AB
Priority claimed from PCT/EP2017/079217 external-priority patent/WO2018091473A1/fr
Publication of CA3040014A1 publication Critical patent/CA3040014A1/fr
Application granted granted Critical
Publication of CA3040014C publication Critical patent/CA3040014C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne un film comprenant un sel d'alginate d'un cation monovalent ou d'un mélange de sels d'alginate contenant au moins un sel d'alginate d'un cation monovalent, et un triptan ou un sel acceptable sur le plan pharmaceutique. Elle concerne également des méthodes pour fabriquer un tel film, et l'utilisation de ce film dans le traitement de pathologies chez un patient humain, en particulier la migraine avec ou sans aura, l'algie vasculaire de la face et la névralgie du trijumeau.
CA3040014A 2016-11-15 2017-11-14 Formulation pharmaceutique Active CA3040014C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201619324 2016-11-15
GB1619324.5 2016-11-15
PCT/EP2017/079217 WO2018091473A1 (fr) 2016-11-15 2017-11-14 Formulation pharmaceutique

Publications (2)

Publication Number Publication Date
CA3040014A1 CA3040014A1 (fr) 2018-05-24
CA3040014C true CA3040014C (fr) 2025-10-28

Family

ID=

Similar Documents

Publication Publication Date Title
US12285521B2 (en) Pharmaceutical formulation
TWI905080B (zh) 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法
JP5941558B2 (ja) シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
CZ45598A3 (cs) Perorální, rychle rozpustné přípravky obsahující dopaminové agonisty
CN117561082A (zh) 治疗重症抑郁和难治性抑郁的方法
CA3040014C (fr) Formulation pharmaceutique
NZ793170A (en) Pharmaceutical formulation
Pathak et al. Recent updates on orally disintegrating thin films